Immuron Limited received FDA approval for Travelan IND Application

Immuron Limited (ASX: IMC) announced that it had received approval from the US Food and Drug Administration to continue with the clinical assessment of Travelan. The Investigational New Drug (IND) application assesses the effectiveness of a single dose of Travelan to avert infectious diarrhea reported by travelers visiting developing countries and among US troops deployed overseas.

As a result of this approval, it will continue with the scheduled clinical trial in the United States. The safety and defensive efficiency of Travelan will be tested using a controlled human infection model clinical trial design. The company also highlighted that it is the sponsor of the IND, and the clinical study will be directed by the Contract Research Organisation Pharmaron CPC, Inc at its FDA-examined clinical research facility situated in Baltimore, Maryland, in the USA.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com